Next to "big guys driving the price down to get your shares cheap," there is no sillier statement than "You don't lose money unless you sell.".
The IBB, which topped out at 400 last July, now seems about to retest 250. But I don't think SGYP is that closely linked to the IBB ...or even the XBI.
I think the whole biotech sector is basically going nowhere until the elections are over and the slow realization sets in that there's still a lot of money to be made with a sucessful drug.
... the IBS-C data is good, and IF the CIC NDA is approved, and IF someone comes forward with the money to launch the drug,... this might be worth $4 a share. But If any of these IF's don't happen, stick a fork in it.
Well, I really think that the bloom is off the biotech rose. When the IBB popped on Monday, I trimmed some positions. No doubt some cute little babies are being thrown out with the bathwater, but I don't think SGYP is one of them. I have so little enthusiasm for the sector that when IRWD popped on earnings, I sold 3/4 of my position. I really think that the management of SGYP are scam artists and that the market at large knows this.
But the parable of the laborers in the vineyard, from which this is drawn, actually suggests salvation through grace, rather than works. Here are some texts for future sermons: 1. Lazarus. Dead stock is miraculously reanimated. 2. The Wise Virgins. Those who trimmed their losses survive. 3. The Loaves and Fishes. Stock is diluted again and again, yet all are satisfied.
"Mindover market" has anointed you as "a paid mouthpiece for a powerful hedge fund orchestrating this takedown". In all my many months here, I have never received such accolades. And all this time I thought you were just a guy who'd bought a few puts taunting the longs. The lesson here is that you get a lot more respect for just posting incessantly than you do for actually explaining why this stock is a scam.
And requiescat in pace.
At under 3, down from 10, I don't think you can call this "bloated". I think this may go down to 2.52, and then wobble around in the 2.50 - 3 area for a long time. Perhaps for months. At some point, they will concoct another phony buyout rumor or some other red herring to keep it alive. As long as Jacob and his little crew of cronies can collect their extravagant salaries and bonuses, this will be kept on life support.
A longwinded restatement of the enduring retail myth: "Big guys driving the price down to get your shares cheap."
No one knows who these 'INVESTORS" are or the exact terms of this transaction. As usual, this company provides puffery and no real information. Even if you take the deal at face value, the only certain thing is that the stockholders' interest has been further diluted by another 30 million shares (= over 75 million shares dilution since the beginning of 2015). Oh, there's one other certain thing: Jacob and his cronies will continue to draw down their extravagant salaries and bonuses as long as there's a nickel in the till. My own belief is that Sender left after he was forced to issue that nonsensical news release on March 21 (after a couple of false starts) arguing that the conversion of the note below face value was a wonderful thing since it reduced future interest obligations. Yes, there's nothing a cash-strapped company likes better than having their credit line pulled. ("Good news, honey! The bank is foreclosing on the house! No more pesky mortgage payments!")
What the poster neglected to mention is that the wonderful news he found on Bing was a month-old (4/15) reference on Streetinsider to a "rumor" circulated on an anonymous tweet and credited, as usual, to that unimpeachable source, "Source". The pumpers are getting desperate to stoop this low.
Since you apparently only want to hear from people who agree with you, I will not waste my time pointing out the 5 basic mistakes in your analysis.
PS The next quarterly report will be much stronger than today's. It will reflect income from the sale of Gary Sender's furniture.
Yep, those NDA filings bring in big money. The deal to peddle Astra-Zeneca's gout drug is obviously a way for Ironwood to amortize its existing sales force. Of course, Synergy doesn't have a sales force. But I understand that they have made a deal whereby Gary Jacob will run out on his coffee break and restock the Pez display at the Duane Reid on Lexington Avenue.
No, let's hear the positive spin now. Your loyal followers are waiting to hear what was good about that klunker of a press release.
Do you really think Allergan has poured over half a billion in development and milestone costs into Linzess and plan to spend another billion or so bringing a competitor to market? And if there was even the faintest possibility of this company being acquired for even $4 a share, do you really think they would have just sold a giant chunk of it for $3 a share? That's pretty lousy arbitrage.
Yep, that 30% YOY increase in scripts and the 44% increase in sales sure spell doom. Most of the constipated people in the world are sitting on the can hoping that someone will slip a trial sample of plecanatide under the door. Unfortunately, there is no such thing.
Actually, Mizuho raised their price target today. After your disastrous investment in SGYP, do you really have enough margin left to short IRWD?
Are you guys losing faith? C'mon, what's a $59.9 quarterly loss to a cash-rich company like Synergy?